scholarly journals A Case of Pneumatosis Cystoides Intestinalis during Gefitinib Treatment for Lung Cancer

2021 ◽  
Vol 82 (4) ◽  
pp. 702-706
Author(s):  
Naoto TAKAHASHI ◽  
Kuniyuki KATO ◽  
Yutaka NISHINARI ◽  
Akira SASAKI
Keyword(s):  
Lung Cancer ◽  
Pneumatosis Cystoides Intestinalis ◽  
Gefitinib Treatment

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients

2006 ◽  
Vol 1 (7) ◽  
pp. 629-634 ◽  
Author(s):  
Hideki Endoh ◽  
Yasushi Yatabe ◽  
Takayuki Kosaka ◽  
Hiroyuki Kuwano ◽  
Tetsuya Mitsudomi
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Prolonged Survival ◽  
Lung Cancer Patients ◽  
Gefitinib Treatment ◽  
Egfr Mutated

scholarly journals PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients

2006 ◽  
Vol 1 (7) ◽  
pp. 629-634 ◽  
Author(s):  
Hideki Endoh ◽  
Yasushi Yatabe ◽  
Takayuki Kosaka ◽  
Hiroyuki Kuwano ◽  
Tetsuya Mitsudomi
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Prolonged Survival ◽  
Lung Cancer Patients ◽  
Gefitinib Treatment ◽  
Egfr Mutated

scholarly journals Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment

2018 ◽  
Vol 4 (1) ◽  
Author(s):  
Liang Wang ◽  
Wen Peng ◽  
Tianming Wu ◽  
Pengchi Deng ◽  
Ying-Lan Zhao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gefitinib Treatment

Predictive and prognostic impact of plasma vascular endothelial growth factor levels in non-small-cell lung cancer patients treated with gefitinib

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13030-13030
Author(s):  
T. Sone ◽  
K. Kasahara ◽  
Y. Tanbo ◽  
S. Tamori ◽  
T. Araya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Small Cell ◽  
Egfr Mutations ◽  
Vascular Endothelial ◽  
Small Cell Lung ◽  
Gefitinib Treatment ◽  
Nsclc Patients ◽  
Endothelial Growth Factor ◽  
Vegf Level

13030 Background: In non-small cell lung cancer (NSCLC), sensitivity to gefitinib is associated with activating mutations of the epidermal growth factor receptor (EGFR). Tumor samples obtained for diagnosis of NSCLC are limited and often unsuitable for analysis of mutations. Other biomarkers are thus needed. We previously reported that serum vascular endothelial growth factor (VEGF) levels were significantly lower in responders to gefitinib than non-responders. To assess levels of circulating VEGF as a predictive and prognostic marker of gefitinib treatment in NSCLC patients, we examined the associations between plasma VEGF levels before gefitinib treatment and clinical outcome. Methods: Eighty four NSCLC patients treated with gefitinib were enrolled into this investigation. Plasma VEGF levels were measured in blood samples before gefitinib administration. Patients were grouped according to VEGF level around a cut-off of 80.7 pg/ml, based on results from normal controls. Response to gefitinib was judged using RECIST guidelines. Time to progression (TTP) and overall survival (OS) following gefitinib treatment were calculated using Kaplan-Meier methods. Groups were compared using log-rank test. We evaluated the immunohistochemical expression of VEGF and EGFR mutations in tumor samples from 37 patients. Results: Response rate was significantly higher with low VEGF level than with high VEGF level (p = 0.0010). Multivariate analysis for response to gefitinib including sex, histology, smoking status, performance status and plasma VEGF level identified only low VEGF level as predictive of response to gefitinib. Low VEGF level was also correlated with prolonged median TTP (4.1 months vs. 1.1 months, p = 0.0081) and OS (11.1 months vs. 5.4 months, p = 0.0290). Multivariate analysis for survival revealed low VEGF level as associated with prolonged TTP (p = 0.0081) and OS (p = 0.0708). Plasma VEGF level was not associated with either VEGF expression or EGFR mutations of tumor tissue. Conclusions: Our results suggest that plasma VEGF levels before gefitinib treatment are predictive of response to gefitinib and prognostic of patients who receive gefitinib. [Table: see text]

Gefitinib treatment affects androgen levels in non-small cell lung cancer patients

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 7290-7290
Author(s):  
M. Nishio ◽  
F. Ohyanagi ◽  
A. Horiike ◽  
Y. Satoh ◽  
S. Okumura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Gefitinib Treatment ◽  
Androgen Levels
Sign in / Sign up

Export Citation Format

Share Document